- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06388707
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
A Prospective, Open-label, Single-arm, Multi-center, Pilot Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Unilateral or Bilateral Temporal Lobe Epilepsy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study aims to demonstrate the safety and preliminary efficacy of LIFU neuromodulation in DR-TLE patients, showing its ability to decrease targeted neuronal activity and alleviate epileptic seizures.
Patients diagnosed with epilepsy who meet all eligibility criteria may participate in this study by providing informed consent, either in person or through their legal representative. Eligible patients will undergo a 2-month baseline observation screening period and will be asked to keep a 8-week seizure diary. This diary will serve as a baseline prior to treatment and will continue to be recorded throughout the treatment and follow-up period.
This study will enroll a maximum of 8 eligible patients through competitive enrollment. Patients will receive a total of 6 FUS treatments over 3 consecutive weeks using assigned ultrasound exposure doses generated by the NaviFUS System. Following treatment, there will be a 12-week follow-up period. Patients will be allowed concomitant use of anti-seizure medications (ASMs) throughout the whole study period.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Sheang-Tze Fung, Ph.D.
- Phone Number: 167 02-25860560
- Email: stfung@navifus.com
Study Contact Backup
- Name: Arthur Lung, Ph.D.
- Email: arthur.lung@navifus.com
Study Locations
-
-
California
-
Palo Alto, California, United States, 94305
- Stanford University School of Medicine
-
Contact:
- Robert Fisher, M.D., Ph.D.
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Contact:
- Ellen Bubrick, M.D.
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University Of Virginia School of Medicine
-
Contact:
- Nathan Fountain, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients ≥ 18 years of age at the time of enrollment.
- Patients with drug-resistant temporal lobe epilepsy (DR-TLE), defined as failure of adequate trials of two tolerated, appropriately chosen and used anti-epileptic drug schedules (whether as monotherapies or in combination).
- Focal-onset seizures with or without secondary generalization and no more than two known seizure onset zones (seizure foci), at least one which is in the mesial temporal lobe.
- At least 4 focal-onset seizures with objectively visible or significantly disabling manifestations in the 8-week baseline and at least one seizure per month in the baseline.
- MRI and EEG within the past 3 years. At least one prior EEG should demonstrate interictal or ictal focal epileptiform findings.
- Patients with the central of FUS exposure region are located at least 30 mm distance beneath the skull bone.
- Patients must be on a stable regimen of anti-epileptic drugs (AEDs) for at least 30 days at the time of enrollment, except for rescue benzodiazepines or occasional extra doses of ongoing medicines, as required.
- Females of childbearing potential must have a negative pregnancy test prior to the first treatment. Females of childbearing potential and male patients with a partner of childbearing potential must agree to follow acceptable method of contraception (as outlined below) from prior to the first study treatment to 3 months after the last study treatment. Standard acceptable methods include use of highly effective method of contraception, including: hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, spermicide, vasectomy, intrauterine device, and abstinence from sex.
- Patients are able and willing to have their hair shaved in the region where the coupling membrane will touch (or if they prefer, whole head).
- Patients are able to complete all clinical trial-related questionnaires in English, including with the use of a suitable interpreter.
- Patients or their legal representatives are able to provide written informed consent for participation in the trial and comply with study requirements in the opinion of the Investigator during the study period.
Exclusion Criteria:
- Patients who have primary generalized epilepsy, mixed focal and generalized epilepsy, or any history of non-epileptic seizures.
- Patients who have experienced tonic-clonic status epilepticus in the 12 months before the time of enrollment in the study. Subjects with focal status epilepticus may be considered at the discretion of the Investigator.
The only feasible sonication pathway to the seizure onset zones involves either:
- Skull area is covered by previous surgical site(s), scars, scalp disorders (e.g., eczema, psoriasis), or scalp atrophy.
- Clips or other metallic implanted objects in the skull or brain, except shunts.
- A prior craniotomy site.
- Patients with a potentially acute or progressive neurologic disorder (e.g., brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).
- Implanted electronic device, for example, implanted cardioverter-defibrillator (ICD), cardiac pacemaker, permanent medication pumps, cochlear implants, responsive neurostimulator, deep brain stimulation (DBS), or other electronic devices implanted in the brain. If a patient has a working Vagus Nerve Stimulator (VNS) in place, the settings should remain stable throughout the trial and the device will be turned off prior to each sonication treatment and then turned back on afterward.
- Patients with severe depression, active suicidal ideation, or behavior of type 4 or 5 in the C-SSRS, active psychosis (excluding time-limited postictal psychosis), or psychiatric hospitalization in the year before time of enrollment.
- Patient has an IQ < 70, based on the Wechsler Abbreviated Scale of Intelligence (WASI-II or other Wechsler IQ measure).
- Coexisting medical problems of sufficient severity to limit compliance with or interpretation of the study.
- Patients have received an investigational drug or an investigational device within 4 weeks prior to the first treatment.
- Radiofrequency thermocoagulation (RFTC) within 2 months before time of enrollment.
- Known history of substance or alcohol abuse within the past year, not counting marijuana.
- Pregnant or breast-feeding women.
- Any other condition that, in the Investigator's judgment, might affect study endpoints or might increase the risk to the patients or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events (AEs)
Time Frame: up to 23 weeks
|
The incidence and severity of AEs associated with LIFU neuromodulation in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy.
|
up to 23 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in seizure frequency
Time Frame: up to 23 weeks
|
The changes in patient's seizure frequency during and after treatment will be assessed based on the seizure diaries.
|
up to 23 weeks
|
Change from baseline in electroencephalography (EEG) epileptiform discharges
Time Frame: up to 15 weeks
|
The change in patient's epileptiform discharges after treatment will be assessed based on the EEG recording.
|
up to 15 weeks
|
Days of seizure-free
Time Frame: up to 23 weeks
|
The changes in number of seizure-free days after FUS treatment(s).
|
up to 23 weeks
|
Changes from baseline in Beck Anxiety Inventory (BAI)
Time Frame: up to 23 weeks
|
BAI is a 21-question multiple-choice self-report inventory that is used to measure the severity of anxiety.
Each answer is scored on a scale value of 0 (not at all) to 3 (severely).
Higher total scores indicate more severe anxiety symptoms.
|
up to 23 weeks
|
Changes from baseline in Beck Depression Inventory (BDI-II)
Time Frame: up to 23 weeks
|
BDI-II, a 21-question multiple-choice self-report inventory, is a psychological test used to measure the severity of depression.
Each answer is rated on a scale of 0 (none at all) to 3 (severe).
Higher total scores indicate more severe depressive symptoms.
|
up to 23 weeks
|
Changes from baseline in Personal Impact of Epilepsy Scale (PIES)
Time Frame: up to 23 weeks
|
PIES is a 25-item multiple-choice self-report inventory that is used to evaluate the overall impact of seizures, side effects, comorbidities, and overall quality of life for people with epilepsy.
Each answer is rated by patient on a scale value of 0 (best) to 4 (worst).
Lower total PIES scores reflect better overall status.
|
up to 23 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in subjective seizure strength
Time Frame: up to 23 weeks
|
The changes in patient's seizure strength during and after treatment will be assessed based on the seizure diaries.
|
up to 23 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Chen SG, Tsai CH, Lin CJ, Lee CC, Yu HY, Hsieh TH, Liu HL. Transcranial focused ultrasound pulsation suppresses pentylenetetrazol induced epilepsy in vivo. Brain Stimul. 2020 Jan-Feb;13(1):35-46. doi: 10.1016/j.brs.2019.09.011. Epub 2019 Sep 24.
- Chu PC, Yu HY, Lee CC, Fisher R, Liu HL. Pulsed-Focused Ultrasound Provides Long-Term Suppression of Epileptiform Bursts in the Kainic Acid-Induced Epilepsy Rat Model. Neurotherapeutics. 2022 Jul;19(4):1368-1380. doi: 10.1007/s13311-022-01250-7. Epub 2022 May 17.
- Lee CC, Chou CC, Hsiao FJ, Chen YH, Lin CF, Chen CJ, Peng SJ, Liu HL, Yu HY. Pilot study of focused ultrasound for drug-resistant epilepsy. Epilepsia. 2022 Jan;63(1):162-175. doi: 10.1111/epi.17105. Epub 2021 Nov 2.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NF-2022-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on NaviFUS System
-
Genovate-NaviFUS (Australia) Pty Ltd.Genovate Biotechnology Co., Ltd.,; NaviFUS CorporationRecruitingDrug Resistant Epilepsy | Epilepsy, Temporal LobeAustralia
-
NaviFUS CorporationRecruitingDrug Resistant EpilepsyTaiwan
-
NaviFUS CorporationRecruitingRecurrent GlioblastomaTaiwan
-
NaviFUS CorporationChang Gung Memorial HospitalCompletedGlioma | Neoplasms | Glioblastoma | Neoplasms, Nerve Tissue | Brain Tumor | Glioblastoma MultiformeTaiwan
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
National Taiwan University HospitalNot yet recruitingStroke | Focused UltrasoundTaiwan
-
NaviFUS CorporationChang Gung Memorial HospitalCompletedGlioma | Neoplasms | Glioblastoma | Neoplasms, Nerve Tissue | Brain Tumor | Glioblastoma MultiformeTaiwan
-
NaviFUS CorporationNaviFUS US LLCNot yet recruitingGlioma | Neoplasms | Glioblastoma | Neoplasms, Nerve Tissue | Brain Tumor | Glioblastoma MultiformeUnited States
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil